Lucid Diagnostics (NASDAQ:LUCD) Releases Earnings Results, Misses Estimates By $0.03 EPS

Lucid Diagnostics (NASDAQ:LUCD) posted its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03), FiscalAI reports. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million.

Here are the key takeaways from Lucid Diagnostics’ conference call:

• Lucid secured a VA Federal Supply Schedule (FSS) contract for EsoGuard at a Medicare-aligned price (~$1,938), opening access to ~170 VA medical centers and a clinically relevant 9M‑patient veteran population.
• Commercial traction accelerated in Q4 with 3,664 tests (above the 2,500–3,000 target), a 29% sequential volume increase and $1.5M of recognized revenue (24% sequential growth).
• Largest real‑world study to date (~12,000 at‑risk patients) showed strong operational performance for EsoCheck/EsoGuard — 95% technical success, 95% of procedures <2 minutes and 100% safety — supporting scalability and payer discussions.
• Management expects a draft Medicare LCD soon after favorable MolDX engagement (followed by a 45‑day public comment period); final coverage would enable retroactive Medicare payments but timing remains uncertain.
• Liquidity and dilution risk: year‑end cash was $34.7M with an average burn of ~$11.1M/quarter, and upcoming Series B conversions will materially increase share count, implying funding/OpEx discipline is required.

Lucid Diagnostics Stock Performance

Shares of LUCD stock traded down $0.05 during trading hours on Friday, hitting $1.11. 163,808 shares of the company were exchanged, compared to its average volume of 1,317,338. The company has a 50 day simple moving average of $1.30 and a two-hundred day simple moving average of $1.18. The firm has a market cap of $152.14 million, a P/E ratio of -1.06 and a beta of 1.18. Lucid Diagnostics has a fifty-two week low of $0.95 and a fifty-two week high of $1.80.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LUCD. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Ascendiant Capital Markets upped their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research report on Thursday. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $3.94.

Trending Headlines about Lucid Diagnostics

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Strong commercial traction: Lucid reported 29% sequential test-volume growth and signaled expanded access into the U.S. Department of Veterans Affairs network, which supports future revenue scaling. Seeking Alpha Article
• Positive Sentiment: Revenue beat and operational metrics: 4Q25 revenue was $1.5M (above the $1.39M consensus) and the company processed 3,664 EsoGuard tests, highlighting topline momentum. PR Newswire Release
• Positive Sentiment: Analyst support: Needham reaffirmed a Buy rating and set a $3.00 price target, providing a visible upside reference for investors. Benzinga Note
• Positive Sentiment: Balance-sheet strength: The company reported roughly $34.7M in cash and year-over-year revenue growth, which eases near-term funding concerns. Quiver Quantitative
• Neutral Sentiment: Materials and transparency: The earnings call transcript, slide deck and webcast are available for investors to assess management’s guidance and commercialization plans. Slide Deck / Press Release
• Negative Sentiment: Earnings miss and continued losses: Lucid reported EPS of -$0.10 versus consensus -$0.07 and remains unprofitable with negative gross profit and operating losses—a reminder of execution and margin risks. Earnings Transcript
• Negative Sentiment: Institutional churn: Several large holders reduced positions in Q4 (per reporting), which could pressure liquidity or sentiment if selling continues. Quiver Quantitative

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Centiva Capital LP acquired a new stake in Lucid Diagnostics in the third quarter worth $25,000. Abel Hall LLC bought a new stake in Lucid Diagnostics in the fourth quarter valued at $33,000. JPMorgan Chase & Co. raised its holdings in shares of Lucid Diagnostics by 71,026.1% during the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after purchasing an additional 32,672 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Lucid Diagnostics during the 1st quarter worth about $39,000. Finally, Invesco Ltd. bought a new position in shares of Lucid Diagnostics during the 2nd quarter worth about $41,000. 74.01% of the stock is owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.